Table 1 Characteristics of lung transplant recipients entering the present study
Patient | Age | Sex | Disease | CMV | CMV | Samples | Follow | Steroid | ||
|---|---|---|---|---|---|---|---|---|---|---|
(yr) | status* | infection | studied | -up | dose | |||||
episodes | (mo) | (mg/kg) | ||||||||
† (n) | ** | |||||||||
D | R | BAL | BAL | |||||||
CMV | CMV | |||||||||
+ (n) | - (n) | |||||||||
1 | 25 | M | Idiopathic pulmonary | + | + | 1 | 1 | 0 | 1 | 0.7 (-) |
fibrosis | ||||||||||
2 | 53 | M | Paracicatricial | + | + | 2 | 1 | 2 | 17 | 0.2 |
emphysema | (0.2–0.5) | |||||||||
3 | 56 | F | Lymphangiomyomatosis | + | + | 8 | 4 ‡ | 6 | 19 | 0.35 |
(0.2–15) | ||||||||||
4 | 18 | F | Cystic fibrosis | + | - | 5 | 2 | 2 | 11 | 0.2 |
(0.2–0.9) | ||||||||||
5 | 48 | M | Idiopathic pulmonary | - | + | 4 | 2 | 2 | 5 | 0.9 |
fibrosis | (0.3–15) | |||||||||
6 | 20 | M | Cystic fibrosis | - | + | 4 | 2 | 1 | 5 | 0.8 |
(0.8–1) | ||||||||||
7 | 42 | M | Panlobular emphysema | - | + | 4 | 2 | 2 | 15 | 0.25 |
(0.2–0.9) | ||||||||||
8 | 37 | F | Primary pulmonary | - | + | 6 | 3 | 2 | 16 | 0.2 |
hypertension | (0.2–15) | |||||||||
9 | 27 | M | Cystic fibrosis | - | - | 0 | 0 | 2 | 7 | 0.3 |
(0.2–0.4) | ||||||||||
10 | 42 | M | Centrolobular | - | - | 0 | 0 | 1 | 24 | 0.2 (-) |
emphysema | ||||||||||
11 | 24 | F | Cystic fibrosis | - | - | 0 | 0 | 5 | 30 | 0.2 |
(0.2–1) | ||||||||||
12 | 23 | M | Cystic fibrosis | - | - | 0 | 0 | 6 | 42 | 0.2 |
(0.2–0.2) | ||||||||||